A Focus on Women’s Health


Latest News and Events


What is HSDD?


Welcome to Ovoca Bio

Ovoca Bio is a clinical-stage biopharmaceutical company with a focus on women’s health. Founded and incorporated in Ireland, the business currently operates in Ireland, the UK and Russia. Ovoca Bio is currently developing Orenetide, a novel medicinal treatment for premenopausal women with hypoactive sexual desire disorder (HSDD), a condition characterized by a distressing lack or loss of sexual desire affecting an estimated ~4 million women in the US with similar patient estimates in Europe. The condition represents a significant area of high unmet medical need with few and challenging treatment options.

About Us

Find out more about us our management team and Board of Directors


Orenetide, a treatment for premenopausal women with hypoactive sexual desire disorder

News & Events

Read the latest news from Ovoca Bio and conferences we will be attending

Our Vision & Approach

Ovoca Bio’s vision is to become a leader in the research and development of, and commercial partner of choice for, novel medicines in areas of high unmet need that affect women.

The Company has filed for approval for the marketing of Oorenetide in Russia and has commenced development of the drug for major global markets, with special focus on the US and Europe.

Ovoca Bio will consider opportunities to license commercialisation rights and/or collaborate with global pharmaceutical companies, regional partners or other qualified potential partners where they would accelerate the availability of current plus future product candidates to patients in need.

Ovoca Bio owns a patent portfolio that provides broad effective protection of its technology and lead product candidate. The Company intends to continue to leverage this patent portfolio and selectively add to it, to develop and commercialise its initial product candidate and potentially future ones.